Sernova Showcases Revolutionary Cell Pouch System™ Data for Treating Hypothyroidism at ATA Meeting

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 29, 2023 - Sernova Corp. SVA SEOVF (FSE/XETRA:PSH), recognized for their pioneering efforts in cell-based therapeutics, has presented promising new data at the American Thyroid Association (ATA) Annual Meeting, focusing on the potential of their Cell Pouch System™ as a radical treatment for post-operative hypothyroidism. This gathering, which took place in Washington, D.C., drew together leading experts from September 27 to October 1, 2023.

Groundbreaking Findings:

The presentation highlighted the Cell Pouch System™'s significant results. Implanting thyroid tissue into the pre-vascularized Cell Pouch™ post thyroidectomy showed normalized levels of vital thyroid hormones, such as free thyroxine (FT4) and triiodothyronine (T3). Beyond hormone restoration, a noteworthy peak and subsequent decline of thyroid stimulating hormone (TSH) hinted at the reactivation of intrinsic thyroid feedback mechanisms. Six months after re-implantation, advanced imaging and histological assessments confirmed the viability and functionality of thyroid tissues within the Cell Pouch™.

Implications and Progress:

'Patients undergoing thyroidectomy frequently face a lifetime reliance on thyroid hormone replacements, leading to potential ongoing symptoms like weight gain and cognitive issues which adversely affect life quality,' explained Cynthia Pussinen, CEO of Sernova. The Cell Pouch System™, as per Sernova's vision, could restore normal thyroid function thus enhancing patient well-being. With one eye on expediting the developmental process, the corporation is evaluating market opportunities for their thyroid program.

The U.S. sees an annual count of about 150,000 thyroidectomies, presenting a substantial commercial prospect. Sernova's prospective inaugural product would employ a patient's own healthy thyroid tissue from benign thyroidectomy, circumventing the need for immune suppression medications. Their ambitions also include a second-generation treatment utilizing stem cells for a wider hypothyroid demographic.

Poster 323, titled 'Auto-Transplantation of Rat Thyroid into a Pre-Vascularized Retrievable Cell Pouch™ Device for the Treatment of Post-Operative Hypothyroidism' and presented by Dr. Arash Memarnejadian, was showcased on September 29, standing out as a beacon of innovative healthcare solutions.

Building a Brighter Future:

Sernova is on the front lines of treating chronic diseases through cellular therapies. They're currently striving towards a 'functional cure' for insulin-dependent diabetes with the Cell Pouch System™ and exploring additional applications including treatments for hemophilia A. Their recent partnership with Evotec EVO opens a pathway to industrial-scale development of stem cell-derived islet therapies for diabetes. Sernova's vision extends further, developing immune protection strategies for cell therapies in collaboration with the University of Miami.

The forward-looking nature of biotech brings myriad challenges, including the necessity for comprehensive testing, regulatory approvals, and the continual quest for financial support. Despite the unpredictable journey, Sernova's leadership remains committed to delivering innovative, life-improving solutions to patients worldwide.

Sernova, Thyroid, ATA